Filing Season Finds: Thursday, March 16

| About: OraSure Technologies, (OSUR)

Summary

We pulled this highlight from yesterday’s research of 48 10-K filings, from which our robo-analyst technology collected 6,034 data points.

Our analyst team used this data to make 964 forensic accounting adjustments with a dollar value of $135 billion.

Analyst Lindsay Bohannon found an unusual item yesterday in OraSure Technologies’ (OSUR) 10-K.

Our latest forensic accounting red flag is from a small medical device company with unsustainable growth driven by a one-time gain.

We pulled this highlight from yesterday's research of 48 10-K filings, from which our robo-analyst technology collected 6,034 data points. Our analyst team used this data to make 964 forensic accounting adjustments with a dollar value of $135 billion. The adjustments were applied as follows:

  • 390 income statement adjustments with a total value of $11 billion
  • 407 balance sheet adjustments with a total value of $55 billion
  • 167 valuation adjustments with a total value of $69 billion

Figure 1: Filing Season Diligence

Sources: New Constructs, LLC and company filings.

We believe this research is necessary to close the gap between the suitability and fiduciary standard of investment advice services.

Today's Forensic Accounting Needle In A Haystack Is For Health Care Investors

Analyst Lindsay Bohannon found an unusual item yesterday in OraSure Technologies' (NASDAQ:OSUR) 10-K.

On page 62, OSUR disclosed $5.4 million in non-recurring revenue as the result of the early termination of a promotion agreement with AbbVie (NYSE:ABBV). This hidden non-operating income helped OSUR report GAAP earnings of ~$20 million, a 140% gain from 2015. Removing this non-operating income, along with other adjustments, revealed that OSUR's net operating profit after tax (NOPAT) grew by 80% to ~$14 million.

2016 was still a great year for OSUR, and it earned its best return on invested capital (ROIC) in over a decade. Our research in the footnotes shows, however, that its growth trajectory is not as impressive as GAAP numbers suggest.

This article originally published here on March 16, 2017.

Disclosure: David Trainer, Lindsay Bohannon, and Sam McBride receive no compensation to write about any specific stock, sector, style, or theme.

Follow us on Twitter (#filingseasonfinds), Facebook, LinkedIn, and StockTwits for real-time alerts on all our research.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

About this article:

Expand
Tagged: , , , Medical Instruments & Supplies
Want to share your opinion on this article? Add a comment.
Disagree with this article? .
To report a factual error in this article, click here